Cancer immunotherapy is one of the most promising research areas in the field of cancer therapy, with immuno-oncology mouse models at the helm of available research tools. Major pharmaceutical companies in the world have devoted great efforts to developing cancer immunity-related treatment methods, with clinical trial results showing that the treatment efficacy is very high. Furthermore, Science magazine ranked cancer immunotherapy to be first place among the top ten scientific breakthroughs in 2013.
Immune checkpoints are molecules in the immune system that either turn up (co-stimulatory molecules) or turn down (inhibitory molecules) immune signals. Tumors can use these checkpoints to protect themselves from immune system attacks, particularly by T cells. Checkpoint therapy can block inhibitory checkpoints or activate stimulatory molecules, restoring immune system function. In recent years, immune checkpoint drugs have become an important novel cancer treatment, as have immuno-oncology mouse models. Biocytogen has prepared and validated a series of immune checkpoint humanized mice that can serve as immuno-oncology mouse models for in vivo efficacy evaluation of human immune checkpoint antibodies.
Key features of Biocytogen’s humanized immune checkpoint mice:
- Pure C57BL/6 genetic background leads to more consistent and reliable experimental results. Biocytogen’s humanized immune checkpoint mice are all developed on the C57BL/6 genetic background, which is most commonly used in oncology, physiology, immunology and genetics studies.
- The humanized mice are carefully designed and generated to maintain biological functions and ensure more reliable drug validation. Biocytogen has developed a wealth of experience in animal model development, with specific experience in humanized immuno-oncology mouse model design. Our project managers are well equipped to fully consider all factors that may interfere with the expression of humanized proteins and to design a detailed, scientifically accurate plan to ensure sufficient humanization, humanized protein expression, and intact signal transduction. With humanized mice, in vivo efficacy evaluation of humanized immune checkpoint antibodies or inhibitors becomes even more reliable and dependable.
Single Humanized Immune-checkpoint Mice
Product | Product No | Background |
---|---|---|
B-dPD-1 mice | 110022 | C57BL/6 |
B-h4-1BB mice | 110004 | C57BL/6 |
B-hB7-H3 mice | 110028 | C57BL/6 |
B-hBTLA mice | 110005 | C57BL/6 |
B-hC5AR1 Mice | 110078 | C57BL/6 |
B-hCALCRL mice | 110115 | C57BL/6 |
B-hCCR5 mice | 110099 | C57BL/6 |
B-hCCR8 mice | 110096 | C57BL/6 |
B-hCD226 mice | 110869 | C57BL/6 |
B-hCD24 mice | 110767 | C57BL/6 |
B-hCD27 mice | 110006 | C57BL/6 |
B-hCD28 mice | 110007 | C57BL/6 |
B-hCD33 mice | 110823 | C57BL/6 |
B-hCD38 mice | 110046 | C57BL/6 |
B-hCD39 mice | 110792 | C57BL/6 |
B-hCD3E mice | 110008 | C57BL/6 |
B-hCD40 mice | 110009 | C57BL/6 |
B-hCD44 mice | 110961 | C57BL/6 |
B-hCD47 mice | 110010 | C57BL/6 |
B-hCD47 mice(C) | 110615 | BALB/c |
B-hCD5 mice | 111125 | C57BL/6 |
B-hCD52 mice | 110817 | C57BL/6 |
B-hCD73 mice | 110027 | C57BL/6 |
B-hCD73 mice plus | 110047 | C57BL/6 |
B-hCD79B mice | 111096 | C57BL/6 |
B-hCD94 Mice | 110044 | C57BL/6 |
B-hCSF2RB mice | 110735 | C57BL/6 |
B-hCTLA4 mice | 110011 | C57BL/6 |
B-hCXCR2 mice | 110816 | C57BL/6 |
B-hCXCR5 mice | 110970 | C57BL/6 |
B-hETAR mice | 110108 | C57BL/6 |
B-hGARP mice | 110102 | C57BL/6 |
B-hGITR mice | 110012 | C57BL/6 |
B-hGLP1R mice | 110106 | C57BL/6 |
B-hLAG3 mice | 110013 | C57BL/6 |
B-hLAG3 mice plus | 110025 | C57BL/6 |
B-hNKG2A mice | 110041 | C57BL/6 |
B-hOX40 mice | 110014 | C57BL/6 |
B-hOX40L mice | 110043 | C57BL/6 |
B-hPD-1 mice | 110003 | C57BL/6 |
B-hPD-1 mice Plus | 110019 | C57BL/6 |
B-hPD-L1 mice | 110015 | C57BL/6 |
B-hPSGL-1 mice | 111470 | C57BL/6 |
B-hRAGE mice | 111107 | C57BL/6 |
B-hRANKL mice | 110772 | C57BL/6 |
B-hSIGLEC10 mice | 110843 | C57BL/6 |
B-hSIGLEC15 mice | 110121 | C57BL/6 |
B-hSIRPA mice | 110016 | C57BL/6 |
B-hTIGIT mice | 110017 | C57BL/6 |
B-hTIM3 mice | 110018 | C57BL/6 |
B-hTIM4 mice | 110837 | C57BL/6 |
B-hTLR8 Mice | 110104 | C57BL/6 |
B-hVSIR mice | 110049 | C57BL/6 |
Double Humanized Immune-checkpoint Mice
Triple Humanized Immune-checkpoint Mice
Product | Product No | Background |
---|---|---|
B-hPD-1/hLAG3/hTIM3 mice | 130999 | C57BL/6 |
B-hPD-1/hPD-L1/h4-1BB mice | 130569 | C57BL/6 |
B-hPD-1/hPD-L1/hCD40 mice | 131083 | C57BL/6 |
B-hPD-1/hPD-L1/hCD73 plus mice | 131036 | C57BL/6 |
B-hPD-1/hPD-L1/hCTLA4 mice | 130571 | C57BL/6 |
B-hPD-1/hPD-L1/hIL2RA mice | 131078 | C57BL/6 |
B-hPD-1/hPD-L1/hLAG3 plus mice | 130572 | C57BL/6 |
B-hPD-1/hPD-L1/hOX40 mice | 311112 | C57BL/6 |
B-hPD-1/hPD-L1/hTIGIT mice | 130573 | C57BL/6 |
B-hPD-1/hPD-L1/hTIM3 mice | 130574 | C57BL/6 |
B-hPD-1/hPD-L1/hTNFR2 mice | 130849 | C57BL/6 |
B-hPD-1/hSIRPA/hCD47 mice | 130562 | C57BL/6 |
B-hPD-L1/hSIRPA/hCD47 mice | 130561 | C57BL/6 |
Tetra Humanized Immune-checkpoint Mice
Product | Product No | Background |
---|---|---|
B-hPD-1/hPD-L1/hSIRPA/hCD47 mice | 140577 | C57BL/6 |
Other Humanized Mice
Product | Product No | Background |
---|---|---|
B-hA2AR mice | 110120 | C57BL/6 |
B-hCCR2 mice | 110097 | C57BL/6 |
B-hCCR4 mice | 110098 | C57BL/6 |
B-hFcRn mice | 110001 | C57BL/6 |
B-hTLR9 mice | 110103 | C57BL/6 |
Product | Product No | Background |
---|---|---|
B-hSIRPA/hCD47,Prkdc/Il2rg KO mice | 140739 | C57BL/6 |